DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $14.00

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) had its price target boosted by research analysts at Lake Street Capital from $11.00 to $14.00 in a report released on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Lake Street Capital's target price would indicate a potential upside of 257.05% from the stock's current price.

Several other research analysts have also recently commented on DMAC. Craig Hallum increased their price target on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Friday. HC Wainwright raised their target price on shares of DiaMedica Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday.

DiaMedica Therapeutics Stock Down 0.2%

NASDAQ DMAC traded down $0.01 during midday trading on Friday, hitting $3.92. The company had a trading volume of 250,561 shares, compared to its average volume of 109,114. The firm has a fifty day simple moving average of $3.92 and a two-hundred day simple moving average of $4.70. The stock has a market cap of $168.13 million, a price-to-earnings ratio of -6.13 and a beta of 1.17. DiaMedica Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18). During the same quarter last year, the business earned ($0.14) earnings per share. As a group, equities analysts predict that DiaMedica Therapeutics will post -0.59 earnings per share for the current year.

Hedge Funds Weigh In On DiaMedica Therapeutics

Hedge funds have recently bought and sold shares of the company. Cornerstone Wealth Management LLC bought a new stake in shares of DiaMedica Therapeutics during the 1st quarter valued at approximately $62,000. Balyasny Asset Management L.P. bought a new stake in shares of DiaMedica Therapeutics during the 4th quarter valued at approximately $79,000. Raymond James Financial Inc. bought a new stake in shares of DiaMedica Therapeutics during the 4th quarter valued at approximately $83,000. Bank of Montreal Can bought a new stake in shares of DiaMedica Therapeutics during the 4th quarter valued at approximately $84,000. Finally, World Investment Advisors grew its holdings in shares of DiaMedica Therapeutics by 17.0% during the 1st quarter. World Investment Advisors now owns 25,650 shares of the company's stock valued at $97,000 after purchasing an additional 3,735 shares during the last quarter. 10.12% of the stock is owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.